Literature DB >> 2949269

[Mechanisms of action of beta-lactam antibiotics and mechanisms of non-enzymatic resistance].

R Williamson, E Collatz, L Gutmann.   

Abstract

The mode of action of beta-lactam antibiotics, and the non-enzymatic resistance mechanisms to their activity, are intimately linked to the structure and biosynthesis of the bacterial cell wall. The bacteriostatic effect of beta-lactam antibiotics is related to their various interactions and concomitant inhibition of essential enzymes (transpeptidases, carboxypeptidases) involved in the terminal stages of peptidoglycan biosynthesis. These cytoplasmic membrane-associated target enzymes bind the antibiotics covalently, and hence are known as penicillin-binding proteins (PBPs). The bactericidal effect of these antibiotics is due to a second step following on from the inhibition of cell division and growth, in which the activation of an autolytic system causes cell death. Resistance to beta-lactam antibiotics in Gram-positive bacteria, in the absence of a beta-lactamase, is due to various modifications of the PBPs. Such mechanisms are often found in enterococci, pneumococcus, ans staphylococci. With Gram-negative bacteria such modifications of PBPs are only a rare basis for resistance. The presence of an outer membrane brings another factor into the activity of beta-lactam antibiotics, which is the facility with the antibiotics can diffuse through specialised proteins termed porins. It is generally a modification of the amounts of these proteins, or some other components of the outer membrane, which causes the non-enzymatic mechanism of resistance, particularly in species such as Klebsiella, Enterobacter, Serratia and Pseudomonas.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2949269

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  3 in total

1.  A QM/MM study on the enzymatic inactivation of cefotaxime.

Authors:  Ignacio Lizana; Eduardo J Delgado
Journal:  J Mol Model       Date:  2017-06-20       Impact factor: 1.810

2.  Using Small-Molecule Adjuvants to Repurpose Azithromycin for Use against Pseudomonas aeruginosa.

Authors:  Veronica B Hubble; Brittany A Hubbard; Bradley M Minrovic; Roberta J Melander; Christian Melander
Journal:  ACS Infect Dis       Date:  2018-11-29       Impact factor: 5.084

3.  Cephalexin-induced acute generalized exanthematous pustulosis.

Authors:  Matthew DaCunha; Sarah Moore; David Kaplan
Journal:  Dermatol Reports       Date:  2018-10-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.